Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leboeuf

Showing results (891-900 of 1,039) with videos related to

Pageof 104
Sort By:
The Oncologist|July 1, 2025
Mitigation and management of adverse events associated with amivantamab therapyNarjust Florez, Nicole R LeBoeuf, Julia Rotow, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint InhibitorsAi-Tram N Bui, Kevin Tyan, Anita Giobbie-Hurder, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 22, 2013
Human de novo papillary renal-cell carcinomas in a kidney graft: evidence of recipient origin with adenoma-carcinoma sequenceJ Verine, M Varna, P Ratajczak, et al.
The American Journal of Pathology|July 1, 1996
High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic miceK Fukuchi, L Ho, S G Younkin, et al.
Journal for Immunotherapy of Cancer|August 21, 2020
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) serviceOsama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, et al.
Blood Cancer Journal|April 17, 2025
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphomaCecilia Larocca, Ai-Tram N Bui, John T O'Malley, et al.
Frontiers in Digital Health|April 26, 2021
A Crisis-Responsive Framework for Medical Device Development Applied to the COVID-19 PandemicMarc-Joseph Antonini, Deborah Plana, Shriya Srinivasan, et al.
Nature Medicine|March 19, 2013
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stressAndrew Chow, Matthew Huggins, Jalal Ahmed, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and IsraelUlf-Henrik Mellqvist, H Tilman Steinmetz, Aurore Perrot, et al.
Pageof 104

Showing results (891-900 of 1,039) with videos related to

Sort By:
Pageof 104
The Oncologist|July 1, 2025
Mitigation and management of adverse events associated with amivantamab therapyNarjust Florez, Nicole R LeBoeuf, Julia Rotow, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSara Khattab, Guihong Wan, Suzanne Xu, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint InhibitorsAi-Tram N Bui, Kevin Tyan, Anita Giobbie-Hurder, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 22, 2013
Human de novo papillary renal-cell carcinomas in a kidney graft: evidence of recipient origin with adenoma-carcinoma sequenceJ Verine, M Varna, P Ratajczak, et al.
The American Journal of Pathology|July 1, 1996
High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic miceK Fukuchi, L Ho, S G Younkin, et al.
Journal for Immunotherapy of Cancer|August 21, 2020
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) serviceOsama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, et al.
Blood Cancer Journal|April 17, 2025
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphomaCecilia Larocca, Ai-Tram N Bui, John T O'Malley, et al.
Frontiers in Digital Health|April 26, 2021
A Crisis-Responsive Framework for Medical Device Development Applied to the COVID-19 PandemicMarc-Joseph Antonini, Deborah Plana, Shriya Srinivasan, et al.
Nature Medicine|March 19, 2013
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stressAndrew Chow, Matthew Huggins, Jalal Ahmed, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and IsraelUlf-Henrik Mellqvist, H Tilman Steinmetz, Aurore Perrot, et al.
Pageof 104